Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Smith, Kline & French Stories

2009-04-21 12:22:00

PHILADELPHIA, April 21 /PRNewswire-FirstCall/ -- On Wednesday, April 22, 2009 GlaxoSmithKline plc (NYSE: GSK) will announce its first quarter financial results for the three months ended March 31, 2009. It is anticipated that the announcement will be released to the London Stock Exchange at approximately 7:00 AM EDT. At 8:30 AM EDTAndrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. A webcast will begin...

2009-04-20 10:23:47

British pharmaceutical giant GlaxoSmithKline said Monday it agreed to purchase skin-products producer Stiefel Laboratories for $2.9 billion. The deal includes the assumption of $400 million of Stiefel's debt, but will add a robust development pipeline to GlaxoSmithKline's product line, the company said in a statement. The deal also includes a potential $300 million cash payment depending on future performance. The addition of Stiefel's broad portfolio will provide immediate new revenue flows...

2009-04-20 06:00:00

Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion New global business will have combined revenues of approximately $1.5 billion and robust new product pipeline Significant step forward to grow and diversify GSK's business, providing immediate new revenue and synergy opportunities LONDON, April 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Stiefel Laboratories Inc. today announced that they have signed an...

2009-04-16 06:50:00

LONDON, April 16 /PRNewswire-FirstCall/ -- Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company. The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%. The deal will be marginally dilutive to GSK earnings in the first two years but in a video interview Group CEO Andrew Witty...

2009-04-16 06:01:00

- Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value - Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments - Equity split of 85% GSK and 15% Pfizer LONDON and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) today announced they have entered into an agreement to create a new world-leading HIV...

2009-03-11 08:00:00

Fluticasone Propionate Nasal Spray (FLONASE(R)) will be the first product marketed under this arrangement MASON, Ohio, March 11 /PRNewswire/ -- Prasco Laboratories, announced today it has entered into a marketing and distribution agreement with GlaxoSmithKline (NYSE: GSK). FLONASE(R) (fluticasone propionate) Nasal Spray is the first product to be marketed under this agreement. Prasco, as GSK's agent and on GSK's behalf, will solicit orders for, and distribute Fluticasone Propionate Nasal...

b5585972c9c875568f89c3ae6438d9101
2009-02-15 07:37:54

According to the head of British pharmaceutical giant GlaxoSmithKline, the company will begin sharing knowledge of patented treatments, and will cut prices for medication in developing nations. Andrew Witty, in an interview with the British newspaper Guardian, said he believed pharmaceutical companies had an obligation the help treat the poor, and has challenged his competitors to do the same. "We work like crazy to come up with the next great medicine, knowing that it's likely to get used an...

2009-02-10 08:04:00

Industry Leaders Team up to Drive Performance Improvements World Wide LONDON, Ontario, Feb. 10 /PRNewswire/ -- Activplant Corporation (www.activplant.com) announced today that GlaxoSmithKline PLC (GSK) has signed a global framework agreement naming Activplant as a recommended business intelligence solution for their world wide manufacturing sites. The agreement comes after a successful implementation where GSK experienced the ease of use that empowers operators, engineers and management to...

2009-02-05 07:25:00

LONDON, February 5 /PRNewswire-FirstCall/ -- In a video interview Andrew Witty, GlaxoSmithKline CEO, described the pharmaceutical group's results as "robust" in a year that was "always going to be challenging". GSK also announced that it will cease providing EPS guidance, to allow a focus on longer term strategic goals. Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to make very clear what it would take to really make this company strong over the...

2009-01-29 15:31:00

PHILADELPHIA, Jan. 29 /PRNewswire-FirstCall/ -- On Thursday, February 5th, GlaxoSmithKline plc (NYSE: GSK) will announce its year end financial results for the year ended December 31, 2008. The announcement is scheduled for release to the London Stock Exchange at approximately 7:00 AM Eastern Standard Time (EST). At 9:00 AM EST Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. The meeting is available...